Eli Lilly, GLP-1
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...
A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...
Pharmaceutical Technology on MSN3d
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback